

Application No. 10/899,882
Amdt. dated August 22, 2005
Reply to Office Action of May 9, 2005

4

Amendments to the Claims:

1. to 28. (Cancelled)

28. (Currently amended) A method of immunizing a host, which comprises:
administering to the host an attenuated bacteria harbouring a vector
comprising a nucleic acid molecule encoding at least one immunoprotection-
inducing *Chlamydia* protein or a fragment thereof which generates a *Chlamydia*
protein specific immune response and a promoter operatively coupled to said nucleic
acid molecule for expression of said *Chlamydia* protein or fragment thereof by cells
~~in cells~~ of the host but not by said ~~in said~~ attenuated bacteria.

30. (Original) The method of claim 28 wherein said Immunoprotection inducing
Chlamydia protein or fragment thereof is a major outer membrane protein (MOMP)
of a strain of *Chlamydia*.

31. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of
Chlamydia pneumoniae.

32. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of
Chlamydia trachomatis.

33. (Cancelled)

34. (Previously presented) The method of claim 29 wherein said promoter is a
cytomegalovirus promoter.

35. (Previously presented) The method of claim 29 wherein said vector is a plasmid
vector.

36. (Previously presented) The method of claim 35 wherein said plasmid vector is
pcDNA3/MOMP as seen in Figure 5.

Application No. 10/699,882
Amdt. dated August 22, 2005
Reply to Office Action of May 9, 2005

5

8 ~~37~~. (Original) The method of claim ~~28~~ wherein said attenuated bacteria is an attenuated strain of *Salmonella*.

9 ~~38~~. (Original) The method of claim ~~37~~ wherein said attenuated strain of *Salmonella* is an attenuated strain of *Salmonella typhimurium*.

10 ~~39~~. (Original) The method of claim ~~29~~ wherein said administration is effected to mucosal surfaces.

11 ~~40~~. (Original) The method of claim ~~39~~ wherein said administration is effected by intranasal administration.